Maurice P H M Jansen
Overview
Explore the profile of Maurice P H M Jansen including associated specialties, affiliations and a list of published articles.
Author names and details appear as published. Due to indexing inconsistencies, multiple individuals may share a name, and a single author may have variations. MedLuna displays this data as publicly available, without modification or verification
Snapshot
Snapshot
Articles
48
Citations
1009
Followers
0
Related Specialties
Related Specialties
Top 10 Co-Authors
Top 10 Co-Authors
Published In
Published In
Affiliations
Affiliations
Soon will be listed here.
Recent Articles
1.
Isebia K, de Jong A, van Dessel L, de Weerd V, Beaufort C, Helmijr J, et al.
Mol Oncol
. 2025 Mar;
PMID: 40084488
Cell-free circulating tumor DNA (ctDNA) has emerged as a promising biomarker for response evaluation in metastatic castration-resistant prostate cancer (mCRPC). The current study evaluated the modified fast aneuploidy screening test-sequencing...
2.
Zelisse H, van Gent M, Mom C, de Ridder S, Snijders M, Heeling M, et al.
Ann Diagn Pathol
. 2024 Nov;
74:152411.
PMID: 39591762
Fundamental and translational research in ovarian cancer aims to enhance understanding of disease mechanisms and improve treatment and survival outcomes. To support this, we established the Dutch multicenter, interdisciplinary Archipelago...
3.
Helmijr J, Motta G, Jongbloed L, de Weerd V, van Bergen L, Verschoor N, et al.
J Appl Lab Med
. 2024 Jul;
9(5):913-925.
PMID: 39012846
Background: Activating mutations in the phosphatidylinositol-4,5-bisphosphate 3-kinase catalytic subunit alpha (PIK3CA) gene have been detected often in solid tumors. Targeted therapy for mutant PIK3CA is now available in the clinic,...
4.
Zelisse H, de Ridder S, van Gent M, Mom C, Wisman G, Roes E, et al.
Biopreserv Biobank
. 2024 Apr;
22(6):568-577.
PMID: 38682281
Biobanks play a crucial role in fundamental and translational research by storing valuable biomaterials and data for future analyses. However, the design of their information technology (IT) infrastructures is often...
5.
van der Leest P, Rozendal P, Hinrichs J, van Noesel C, Zwaenepoel K, Deiman B, et al.
Clin Chem
. 2024 Mar;
70(5):759-767.
PMID: 38484302
Background: Identification of tumor-derived variants in circulating tumor DNA (ctDNA) has potential as a sensitive and reliable surrogate for tumor tissue-based routine diagnostic testing. However, variations in pre(analytical) procedures affect...
6.
Xu T, Verhagen M, Teeuwssen M, Sun W, Joosten R, Sacchetti A, et al.
Cell Death Differ
. 2024 Feb;
31(3):360-377.
PMID: 38365970
Phenotypic plasticity, defined as the ability of individual cells with stable genotypes to exert different phenotypes upon exposure to specific environmental cues, represent the quintessential hallmark of the cancer cell...
7.
Levink I, Jansen M, Azmani Z, van IJcken W, van Marion R, Peppelenbosch M, et al.
Int J Mol Sci
. 2023 Sep;
24(17).
PMID: 37685923
Molecular profiling may enable earlier detection of pancreatic cancer (PC) in high-risk individuals undergoing surveillance and allow for personalization of treatment. We hypothesized that the detection rate of DNA mutations...
8.
Jongbloed E, Jansen M, de Weerd V, Helmijr J, Beaufort C, Reinders M, et al.
Sci Rep
. 2023 Jun;
13(1):10424.
PMID: 37369746
Next generation sequencing of cell-free DNA (cfDNA) is a promising method for treatment monitoring and therapy selection in metastatic breast cancer (MBC). However, distinguishing tumor-specific variants from sequencing artefacts and...
9.
Zelisse H, van Gent M, de Ridder S, van der Aa M, Van Altena A, Bart J, et al.
Gynecol Obstet Invest
. 2022 Nov;
87(6):389-397.
PMID: 36450222
Objectives: Ovarian cancer has the worst overall survival rate of all gynecologic malignancies. For the majority of patients, the 5-year overall survival rate of less than 50% has hardly improved...
10.
Isebia K, Mostert B, Belderbos B, Buck S, Helmijr J, Kraan J, et al.
Eur J Cancer
. 2022 Nov;
177:33-44.
PMID: 36323051
Background: Metastatic castration-resistant prostate cancer (mCRPC) patients with positive AR-V7 expression in their circulating tumour cells (CTCs) rarely derive benefit from abiraterone and enzalutamide. Design: We performed a prospective, multicenter,...